CoChat

Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives

Purohit, A., Niederberger, V., Kronqvist, M., Horak, F., Grönneberg, R., Suck, R., Weber, B., Fiebig, H., Van Hage, M., Pauli, G., Valenta, R., Cromwell, O. · 2008 · Clinical & Experimental Allergy
Cited by 163

The DOI matches its Crossref record.

Abstract

Summary: Background Birch pollen and pollen from related trees of the Fagales order are a major cause of allergic rhinitis, conjunctivitis, and asthma through the spring season in northern and central Europe. Objective To investigate the clinical effects of injection immunotherapy with genetically modified derivatives of major birch pollen allergen Bet v 1 on pollen‐induced allergic symptoms. Methods A three‐arm double‐blind placebo‐controlled immunotherapy study was conducted with one pre‐seasonal course of treatment using two derivatives of Bet v 1, namely a recombinant Bet v 1 trimer and an equimolar mixture of two recombinant Bet v 1 fragments together representing the whole protein sequence. Analysis of local and systemic adverse events was performed for 124 patients who had received at least one dose of medication. Clinical efficacy was monitored by symptom medication scores and interval scoring in the per protocol‐treated population (n=84). In addition, skin and nasal provocation responses and allergen‐specific antibodies were assessed. Results There were trends towards improvement in the subjects' well‐being and clinical symptoms (nasal scores), although comparisons with a placebo group did not show statistical significance in the main end‐point, the combined symptom medication score. Reductions in skin and nasal sensitivity were observed for some subjects with a trend for the Bet v 1 trimer to be more effective than the fragments. Treatment induced strong IgG1 and IgG4 allergen‐specific antibody responses. Local injection‐site reactions were most frequent in the trimer group affecting 59.5% of patients as opposed to 37.8% and 30.6% in the fragment and placebo groups, respectively. Systemic reactions were elicited more frequently by fragments. A large proportion of adverse side‐effects appeared hours following injections, and might be attributable to concurrent exposure to related pollens. Conclusion Single courses of injection immunotherapy with Bet v 1 allergen derivatives showed trends towards improved well‐being and reduced reactivity to specific allergen provocation, but did not yield significant improvement in the combined symptom medication score in this study.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2222.2008.03042.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 163

Metadata

Authors
Purohit, A., Niederberger, V., Kronqvist, M., Horak, F., Grönneberg, R., Suck, R., Weber, B., Fiebig, H., Van Hage, M., Pauli, G., Valenta, R., & Cromwell, O.
Venue
Clinical & Experimental Allergy
Publisher
Wiley
Published
2008-08-25
Volume
38
Issue
9
Pages
1514-1525
ISSN
  • 0954-7894 (ISSN-L)
  • 1365-2222
OpenAlex
W2047418056
Cited by
163
References
0
FWCI
9.59
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. https://app.cochat.ai/papers/10.1111/j.1365-2222.2008.03042.x
The paper
Purohit, A., Niederberger, V., Kronqvist, M., Horak, F., Grönneberg, R., Suck, R., Weber, B., Fiebig, H., Van Hage, M., Pauli, G., Valenta, R., & Cromwell, O. (2008). Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Clinical & Experimental Allergy. https://doi.org/10.1111/j.1365-2222.2008.03042.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.